Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
IBSRELA®(tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in AdultsFirst Novel Mechanism Therapy to Treat I...
Source: businessinsider.com